MedTrace Logo

A Study of KL590586 in Patients With Advanced Solid Tumors

NCT05265091 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 414

Last updated 2026-05-08

No results posted yet for this study

Summary

An Open, Multi-Center Phase I/II Clinical Study To Evaluate The Safety, Tolerability, Pharmacokinetic Characteristics And Effectiveness Of KL590586 Capsules In Patients With Advanced Solid Tumors Carrying RET Fusion Or Mutant Genes

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

KL590586 Capsule

Product Name: KL590586 Capsules Formulation：Capsule Specification: 10mg; 50mg Ingredients: KL590586, microcrystalline cellulose, mannitol, cross-linked sodium carboxymethylcellulose, colloidal silicon dioxide, magnesium stearate, hydroxypropylmethylcellulose hollow capsule

Sponsors & Collaborators

  • Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Xiangqian Zheng, Professor · Tianjin Medical University Cancer Institute and Hospital

  • Shanghua Jing, Professor · The Fourth Hospital of Hebei Medical University and Hebei Cancer Hospital

  • Anwen Liu, Professor · Second Affiliated Hospital of Nanchang University

  • Yilong Wu, Professor · Guangdong Provincial People's Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-15
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05265091 on ClinicalTrials.gov